RPRX - Royalty Pharma Plc - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

RPRX is currently covered by 6 analysts with an average price target of $45.7. This is a potential upside of $12.35 (37.03%) from yesterday's end of day stock price of $33.35.

Royalty Pharma Plc's activity chart (see below) currently has 31 price targets and 38 ratings on display. The stock rating distribution of RPRX is 94.44% BUY and 5.56% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 2.88% with an average time for these price targets to be met of 26.11 days.

Highest price target for RPRX is $51, Lowest price target is $28, average price target is $41.67.

Most recent stock forecast was given by ANDREW BAUM from CITI on 24-Oct-2024.

Currently out of the existing stock ratings of RPRX, 17 are a BUY (94.44%), 1 are a HOLD (5.56%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$40

$6.85 (20.66%)

$60

6 months 18 days ago
(24-Oct-2024)

0/4 (0%)

$13.27 (49.64%)

Buy

$51

$17.85 (53.85%)

$50

7 months 2 days ago
(10-Oct-2024)

1/17 (5.88%)

$23.21 (83.52%)

186

Buy

$51

$17.85 (53.85%)

$50

8 months 29 days ago
(13-Aug-2024)

0/4 (0%)

$24.77 (94.43%)

Hold

$28

$-5.15 (-15.54%)

$41

11 months 10 days ago
(02-Jun-2024)

1/5 (20%)

$1.58 (5.98%)

49

Buy

$38

$4.85 (14.63%)

$51

1 years 1 months 1 days ago
(11-Apr-2024)

0/3 (0%)

$10.43 (37.83%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RPRX (Royalty Pharma Plc) average time for price targets to be met?

On average it took 26.11 days on average for the stock forecasts to be realized with a an average price target met ratio 2.88

Which analyst has the current highest performing score on RPRX (Royalty Pharma Plc) with a proven track record?

NAVIN JACOB

Which analyst has the current lower performing score on RPRX (Royalty Pharma Plc) with a proven track record?

UMER RAFFAT

Which analyst has the most public recommendations on RPRX (Royalty Pharma Plc)?

Navin Jacob has 13 price targets and 7 ratings on RPRX

Which analyst is the currently most bullish on RPRX (Royalty Pharma Plc)?

Ivan Feinseth with highest potential upside - $24.64

Which analyst is the currently most reserved on RPRX (Royalty Pharma Plc)?

Ashwani Verma with lowest potential downside - -$5.15

Royalty Pharma Plc in the News

Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share increased from $0.01 in the same quarter last year. Is now the time to buy Royalty Pharma? Find out in our full research report....

Royalty Pharma Reports First Quarter 2025 Results

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?